TH‐AB‐207A‐11: Anatomical and Functional Assessment of Coronary Artery Disease Using Low‐Dose Whole‐Organ Dynamic Computed Tomography

Purpose: To evaluate the accuracy of a low-dose, first-pass-analysis (FPA) dynamic computed tomography angiography and perfusion (CTAP) technique, for whole-organ anatomical and functional assessment of coronary artery disease (CAD). Methods: An angioplasty balloon was advanced into the left anterior descending (LAD) coronary artery of five swine (35–45 kg) to induce several levels of stenosis at maximal hyperemia (intracoronary adenosine, 240 µg/min). Reference fluorescence microspheres and intravenous contrast (370 mg/mL iodine, 25 mL, 7 mL/s) were injected centrally and dynamic imaging was performed using a 320-slice CT scanner at 100 kVp and 200 mA. Twenty volume scans were acquired per stenosis level to capture complete aortic and myocardial enhancement curves, but only two volume scans were used for whole-organ dynamic FPA CTAP measurement. All CTAP measurements in the LAD were compared to the reference microsphere perfusion measurements using linear regression, concordance correlation, and Bland-Altman analysis. Results: The result of dynamic FPA CTAP measurement in the LAD was in good agreement with the reference microsphere perfusion measurement (P_CTAP = 1.01 P_MICRO + 0.16, R2 = 0.95). The root mean square error (RMSE) and difference (RMSD) of measurement were 0.51 mL/min/g and 0.47 mL/min/g, respectively. Bland-Altman analysis demonstrated negligible systematic measurement bias. Additionally, the concordance correlation coefficient (CCC) was found to be ρ = 0.97, indicating excellent agreement between dynamic FPA CTAP measurement and the reference microsphere perfusion measurement. Lastly, the effective dose of the proposed technique using the “simulated” two-volume scan CTAP acquisition protocol was 2.6 mSv; much lower than the ∼10 mSv effective dose of current dynamic CTP techniques alone. Conclusion: The results indicate the potential for significant improvements in CAD assessment through low-dose, quantitative dynamic FPA CTAP. Such improvements are afforded through whole-organ CT scanning technology, and have the potential to improve patient outcomes and lead to healthier patient lives. Conflict of Interest (only if applicable): Grant funding from Toshiba America Medical Systems.